Clinical and Experimental Pharmacology and Physiology · 2010 · 35 citations · 35 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyInflammationInnate ImmunityBlood Pressure ManagementCardiovascular DiseaseHypertension ManagementHypertension PharmacotherapyHypertensive Heart DiseaseInflammatory SignalingAngiotensin Ii Receptor BlockersAntihypertensive Drug TherapyAntihypertensive PharmacologyBiglycan BiologyBlood PressureHypertensive Vascular DiseaseMonocyte BiologyRenin-angiotensin-aldosterone System Blockade
1. Recently, we demonstrated that biglycan (BGN) is increased in circulating monocyte cells from hypertensive patients and that angiotensin (Ang) II is able to increase BGN expression. The present study was designed to investigate the effects of treatment with the angiotensin AT(1) receptor antagonist losartan on monocyte BGN mRNA and protein expression in essential hypertension. 2. One hundred and twenty-six newly diagnosed hypertensive patients without additional risk factors for atherosclerosis and cardiovascular disease were treated with 100 mg losartan once daily for 6 months. Biglycan mRNA and protein expression was determined in monocytes isolated from peripheral blood before (T(0)) and after (T(1)) therapy. Plasma levels of interleukin (IL)-6, tumour necrosis factor (TNF)-alpha and high sensitivity C-reactive protein (hs-CRP) were also determined. In addition, BGN mRNA and protein expression was determined after the ex vivo addition of 1 micromol/L AngII to monocytes isolated from 20 randomly selected hypertensive patients. 3. Biglycan mRNA and protein expression, blood pressure and plasma levels of fibrinogen, IL-6, TNF-alpha and CRP were significantly lower at T(1) than at T(0). Variations in BGN expression were associated with inflammatory markers, but not directly with blood pressure. In AngII-stimulated monocytes, BGN mRNA and protein expression was significantly lower at T(1) that at T(0). Moreover, mean BGN mRNA expression in AngII-stimulated monocytes isolated from losartan-treated patients was similar to baseline expression in unstimulated monocytes from untreated patients. 4. The results of the present study show that losartan can reduce BGN expression in monocytes from hypertensive patients, without any linear association with blood pressure, suggesting that the effects of AngII on BGN expression in monocytes may be modulated, in part, by an AT(1) receptor blocker.
35
Quantification of mRNA using real-time RT-PCR
Tania Nolan, Rebecca Hands, Stephen A. Bustin · Nature Protocols · 2006 · 2.3K citations
Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice
Tianshun Xu, Paolo Bianco, Larry W. Fisher et al. · Nature Genetics · 1998 · 611 citations
C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle
Chao‐Hung Wang, Shuhong Li, Richard D. Weisel et al. · Circulation · 2003 · 546 citations